Company news: Boehringer Ingelheim

Share this article:
Boehringer Ingelheim won FDA approval for blood thinner Pradaxa (dabigatran) to prevent stroke in patients with atrial fibrillation (AFib). The twice-daily, oral med, which doesn't require anticoagulation monitoring like warfarin, could capture a sizable portion of the decades-old blood thinner's market. Boehringer Ingelheim, set to launch Pradaxa within days, is reaching the US market ahead of rivals Johnson & Johnson and Bayer, which filed an NDA for their own warfarin replacement, oral anticoagulant Xarelto (rivaroxiban), in 2008, and before Bristol-Myers Squibb and Pfizer, whose apixaban is in Phase III. J&J and Bayer received a complete response letter in 2009 requesting more clinical data on Xarelto, and FDA has yet to hand down a decision. The warfarin replacement market is so big, analysts estimate, that all three drugs should exceed $1 billion in US sales should they be approved. Pradaxa and Xarelto are already approved in other territories, including several countries of the EU.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.